Academe Learn
CBME Curriculum Preview

Page 19 of 19

IM9.1-17 | Anaemia — PBL Case

CLINICAL SETTING

The General Medicine outpatient clinic at a district teaching hospital in Chhattisgarh. Dr Priya is a final-year MBBS student attending her first general medicine outpatient posting under the supervision of Dr Ramesh, the registrar. It is 10 AM on a Wednesday. The next patient is Mrs Lalita Bai, a 32-year-old woman from a village 45 kilometres away. She has come by bus with her husband and her youngest child, a 14-month-old boy she is still breastfeeding. Her husband says: 'She is always tired. She cannot do any work in the fields anymore. She gets breathless walking uphill.' Lalita herself says: 'I have had this for over a year. I thought it was just weakness after the baby.' She is a vegetarian. The family farms rice and grows pulses for their own consumption. She drinks three to four cups of tea with milk daily. She has had four pregnancies — the last two within 30 months of each other. Her periods resumed 8 months after the last delivery and have been heavy, lasting 7-8 days per cycle. Dr Ramesh turns to Priya: 'Let us examine her together. What are you looking for, and where?'

Trigger 1: The Examination — What the Eyes and Hands Find

Dr Ramesh and Priya examine Lalita. They find: marked conjunctival pallor (palpebral conjunctivae almost white); slight pallor of tongue and palmar creases; nail beds pale with a spoon-shaped deformity (koilonychia) in both thumbs; angular stomatitis at both corners of the mouth; no jaundice; no lymphadenopathy; mild smooth glossitis; heart rate 98/min, bounding pulse; a soft systolic flow murmur at the apex, grade 2/6; no hepatomegaly; spleen just palpable at deep inspiration (1 cm below costal margin). There is no frontal bossing, no bone tenderness. Lalita's weight is 44 kg; she appears malnourished. Her CBC result comes back quickly: Hb 6.8 g/dL, MCV 61 fL, MCH 18 pg, RBC count 4.1 million/mcL, RDW 18.4%, WBC 7,200/mcL (normal differential), platelets 310,000/mcL. The technician adds a note: 'Peripheral smear: microcytic hypochromic RBCs, pencil cells, occasional target cells. No abnormal white cells. No parasites seen.'

DISCUSSION POINTS

  • Map each clinical finding in the examination to its underlying pathophysiological mechanism. Which signs are attributable to anaemia severity? Which are specific to iron deficiency? What does koilonychia tell you about the chronicity and severity of the iron deficiency?
  • Calculate the Mentzer index (MCV divided by RBC count). Does this support iron deficiency anaemia or thalassaemia trait? What is the significance of target cells on the smear in this context?
  • What clinical and haematological features distinguish this patient's presentation from megaloblastic anaemia or anaemia of chronic disease at this stage?
Click to reveal Trigger 2: The Iron Studies Result — A Diagnostic Twist (discuss previous trigger first!)

Trigger 2: The Iron Studies Result — A Diagnostic Twist

Iron studies return the next day: serum ferritin 14 mcg/L, serum iron 32 mcg/dL, TIBC 490 mcg/dL, transferrin saturation 6.5%. Dr Ramesh is about to write 'IDA — start oral iron' when the community medicine intern who knows the village points out: 'Both of Lalita's younger siblings have had anaemia since childhood. Her father was told he has thalassaemia trait at a sickle cell screening camp five years ago.' Dr Ramesh pauses: 'So we may not just be dealing with IDA. What else do we need to think about?' He then remembers another concern: Lalita's CBC also shows a CRP of 6 mg/L — mildly elevated. He shows Priya the lab sheet: 'Does the ferritin value of 14 mean the same thing now that we know there is mild inflammation?'

DISCUSSION POINTS

  • The iron studies show a classic IDA pattern (low ferritin, high TIBC, low transferrin saturation). However, the family history raises the possibility of concurrent thalassaemia trait. How does thalassaemia trait change or complicate the interpretation of the iron studies in this patient?
  • Serum ferritin is an acute-phase reactant. With CRP mildly elevated at 6 mg/L, how reliable is a ferritin of 14 mcg/L as a marker of iron store depletion? What additional test, if available, would help clarify whether IDA coexists with thalassaemia trait?
  • If Lalita does have beta-thalassaemia trait in addition to IDA, how does this change the genetic counselling implications — given that her husband is from an area where thalassaemia is prevalent?
Click to reveal Trigger 3: Starting Treatment — But Then She Returns (discuss previous trigger first!)

Trigger 3: Starting Treatment — But Then She Returns

Dr Ramesh decides to treat Lalita for IDA, reasoning that the iron studies overwhelmingly support iron deficiency regardless of any thalassaemia carrier status. He prescribes ferrous sulphate 200 mg thrice daily with dilute lemon juice, to be taken 30 minutes before meals. He also asks for HPLC haemoglobin studies to be sent to confirm or exclude thalassaemia trait. He counsels her about dietary sources of iron and addresses her tea habit. Six weeks later Lalita returns. Her Hb is now 9.2 g/dL — a rise of 2.4 g/dL in 6 weeks, confirming a good response to iron. However, she is distressed: 'My tablets are causing so much constipation and stomach pain. My husband bought a 'health tonic' from the medical shop instead — he says it is safer.' The 'health tonic' is a liquid preparation of ferric ammonium citrate, which her husband has been giving her for the past two weeks instead of the prescribed tablets. Dr Ramesh looks at Priya: 'How do I explain to her why she needs to switch back, and what to do about the side effects?'

DISCUSSION POINTS

  • The patient switched from ferrous sulphate (ferrous iron, Fe2+) to a ferric ammonium citrate tonic (ferric iron, Fe3+). What is the pharmacological difference between ferrous and ferric iron preparations in terms of absorption, and why does it matter clinically for this patient?
  • GI side effects (nausea, constipation, abdominal cramps) are the most common cause of non-adherence to oral iron. What practical strategies can be offered to Lalita to manage these side effects without compromising iron intake? When is parenteral iron justified?
  • What specific counselling message will help Lalita understand WHY she must continue iron for at least 3-6 months after her Hb normalises — and how would you frame this so she complies, given her family's preference for alternatives?
Click to reveal Trigger 4: The Larger Picture — Community, Prevention, and Her Son (discuss previous trigger first!)

Trigger 4: The Larger Picture — Community, Prevention, and Her Son

Lalita's HPLC result returns: HbA 94.2%, HbA2 4.8%, HbF 1.0%. Dr Ramesh explains: 'You are a beta-thalassaemia carrier. Your iron deficiency is real and needed treatment — but there is a second issue now.' He arranges for her husband to be tested: his HPLC shows HbA2 4.6%, confirming he is also a carrier. Dr Ramesh tells the couple: 'Your next pregnancy carries a one-in-four chance of producing a child with thalassaemia major.' He then turns to Lalita's son: Hb 9.8 g/dL, MCV 70 fL — anaemia in a 14-month-old child being breastfed by a severely iron-deficient mother. The district health officer visiting the clinic mentions that the village has a low coverage under the Anaemia Mukt Bharat programme. Dr Ramesh asks Priya: 'If you were designing a community-level intervention for Lalita's village, what would it include, and which of the six target groups under AMB apply to people in this room right now?'

DISCUSSION POINTS

  • Both Lalita and her husband are confirmed beta-thalassaemia carriers. Explain the inheritance pattern and the four possible outcomes in their next pregnancy. What is the role of prenatal diagnosis, and at what gestational age must it be offered?
  • Lalita's 14-month-old son has anaemia (Hb 9.8 g/dL, MCV 70 fL). He is still being breastfed and has recently started complementary feeds. What is the most likely cause of his anaemia, and what is the national programme recommendation for iron supplementation in children aged 6 months to 5 years under Anaemia Mukt Bharat?
  • Identify which of the six Anaemia Mukt Bharat target groups apply to people in this clinical scenario (Lalita, her husband, her son, and the community). What are the specific AMB interventions for each group, and what implementation barrier is most likely in a tribal district of Chhattisgarh?

Group Task Assignments

  • Construct a complete, annotated diagnostic algorithm for a patient presenting with microcytic anaemia in a high-burden Indian setting, explicitly showing the decision points where iron studies differentiate IDA from ACD, thalassaemia trait, and mixed deficiency. Annotate each branch with the test values and cutoffs you would use.
  • Draft the prescribing instructions that Dr Ramesh should give Lalita for ferrous sulphate: exact drug name, dose, elemental iron content, timing, food interactions, expected side effects and how to manage them, black stool explanation, and expected duration. Write this as a patient-facing instruction card suitable for a semi-literate patient in Chhattisgarhi-speaking areas.
  • Prepare a one-page brief for the district health officer on Anaemia Mukt Bharat: its six target population groups, the specific intervention for each group, and three evidence-based barriers to implementation in tribal Chhattisgarh. Recommend one priority intervention based on the case.
  • Debate the clinical question: 'Should all patients with microcytic anaemia in high-burden settings receive empirical iron therapy, or should iron studies be mandatory before prescribing?' Assign one group to each position; both groups should address the cost, clinical risk (e.g., iron overload in thalassaemia), and feasibility dimensions.

Learning Issues

Research these questions and bring your findings to the discussion.

  1. [IM9.7] What is the diagnostic interpretation of the four iron study parameters (serum ferritin, serum iron, TIBC, transferrin saturation) in IDA, ACD, and thalassaemia trait, and how does concurrent inflammation alter the diagnostic reliability of serum ferritin?
  2. [IM9.5] How does the Mentzer index (MCV/RBC count) help distinguish iron deficiency anaemia from thalassaemia trait, and what is the role of HPLC haemoglobin quantification in confirming thalassaemia carrier status?
  3. [IM9.10] What is the correct prescription for oral iron therapy in IDA (preparation, dose, elemental iron content, route, timing, interactions, duration), and when is parenteral iron indicated instead of or in addition to oral therapy?
  4. [IM9.11] What are the six target population groups and corresponding interventions under India's Anaemia Mukt Bharat programme, and what are the specific recommendations for iron supplementation in children aged 6-59 months and pregnant women?
  5. [IM9.16] How should a clinician counsel a patient from a low-literacy, rural background about the importance of completing a 6-month iron course, managing GI side effects, dietary iron sources in a vegetarian Indian diet, and the thalassaemia carrier implications for future pregnancies?